Immigration: The Shaping of Partisan Identity and Presidential Vote Choice

Immigration as an issue is salient in U.S. politics, particularly regarding the 2016 presidential election. Building a wall on the southern border of the United States, expanding border patrol units, and deporting all unauthorized aliens are all salient immigration issues pervasive in the politics of today. The Latino population is often targeted as the population that these issues affect to the greatest extent, and thus, their vote hinges upon the issue. What impact does immigration as an issue have on Latino partisan identity, and in turn, vote choice? The author draws election data from the Cooperative Congressional Election Study and conducts regression analysis to determine the issue of immigration's effect on partisan identity and vote choice. The results show that immigration directly affects both Latino partisan identity and presidential vote choice. The findings point to further research on issue salience and party identification.Political Scienc

Lack of PAH emission toward low-mass embedded young stellar objects

PAHs have been detected toward molecular clouds and some young stars with disks, but have not yet been associated with embedded young stars. We present a sensitive mid-IR spectroscopic survey of PAH features toward a sample of low-mass embedded YSOs. The aim is to put constraints on the PAH abundance in the embedded phase of star formation using radiative transfer modeling. VLT-ISAAC L-band spectra for 39 sources and Spitzer IRS spectra for 53 sources are presented. Line intensities are compared to recent surveys of Herbig Ae/Be and T Tauri stars. The radiative transfer codes RADMC and RADICAL are used to model the PAH emission from embedded YSOs consisting of a PMS star with a circumstellar disk embedded in an envelope. The dependence of the PAH feature on PAH abundance, stellar radiation field, inclination and the extinction by the surrounding envelope is studied. The 3.3 micron PAH feature is undetected for the majority of the sample (97%), with typical upper limits of 5E-16 W/m^2. Compact 11.2 micron PAH emission is seen directly towards 1 out of the 53 Spitzer Short-High spectra, for a source that is borderline embedded. For all 12 sources with both VLT and Spitzer spectra, no PAH features are detected in either. In total, PAH features are detected toward at most 1 out of 63 (candidate) embedded protostars (<~ 2%), even lower than observed for class II T Tauri stars with disks (11-14%). Assuming typical class I stellar and envelope parameters, the absence of PAHs emission is most likely explained by the absence of emitting carriers through a PAH abundance at least an order of magnitude lower than in molecular clouds but similar to that found in disks. Thus, most PAHs likely enter the protoplanetary disks frozen out in icy layers on dust grains and/or in coagulated form.Comment: 13 pages, 9 figures, accepted for publication in A&

Disks and Outflows in CO Rovibrational Emission from Embedded, Low-Mass Young Stellar Objects

Young circumstellar disks that are still embedded in dense molecular envelopes may differ from their older counterparts, but are historically difficult to study because emission from a disk can be confused with envelope or outflow emission. CO fundamental emission is a potentially powerful probe of the disk/wind structure within a few AU of young protostars. In this paper, we present high spectral (R=90,000) and spatial (0.3") resolution VLT/CRIRES M-band spectra of 18 low-mass young stellar objects (YSOs) with dense envelopes in nearby star-froming regions to explore the utility of CO fundamental 4.6 micron emission as a probe of very young disks. CO fundamental emission is detected from 14 of the YSOs in our sample. The emission line profiles show a range of strengths and shapes, but can generally be classified into a broad, warm component and a narrow, cool component. The broad CO emission is detected more frequently from YSOs with bolometric luminosities of <15 Lsun than those with >15 Lsun, and as with CO emission from CTTSs is attributed to the warm (~1000 K) inner AU of the disk. The CO emission from objects with high bolometric luminosity is produced in cooler (~320 K), narrow lines in 12CO and in rarer isotopologues. From some objects, the narrow lines are blueshifted by up to ~10 km/s, indicating a slow wind origin. For other sources the lines are located at the systemic velocity of the star and likely arise in the disk. For a few YSOs, spatially-extended CO and H2 S(9) emission is detected up to 2" from the central source and is attributed to interactions between the wind and surrounding molecular material. Warm CO absorption is detected in the wind of six objects with velocities up to 100 km/s, often in discrete velocity components. That the wind is partially molecular where it is launched favors ejection in a disk wind rather than a coronal or chromospheric wind.Comment: 26 pages, accepted by A&

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Suppressed monocyte gene expression profile in men versus women with PTSD

There have been several attempts to use gene microarrays from peripheral blood mononuclear cells to identify new biological pathways or targets for therapy in Posttraumatic Stress Disorder (PTSD). The few studies conducted to date have yielded an unclear pattern of findings, perhaps reflecting the use of heterogeneous samples of circulating immune cells for analysis. We used gene microarrays on a homogeneous sample of circulating monocytes to test the hypothesis that chronic PTSD would be associated with elevated inflammatory activity and to identify new pathways dysregulated in the disorder. Forty-nine men (24 PTSD+ and 25 age-matched trauma-exposed PTSD− controls) and 18 women (10 PTSD+ and 8 age-matched PTSD− controls) were recruited. Gene expression microarray analysis was performed on CD14+ monocytes, immune cells that initiate and respond to inflammatory signaling. Male subjects with PTSD had an overall pattern of under-expression of genes on monocytes (47 under-expressed versus 4 over-expressed genes). A rigorous correction for multiple comparisons and verification with q-PCR showed that of only 3 genes that were differentially expressed, all were under-expressed. There was no transcriptional evidence of chronic inflammation in male PTSD+ subjects. In contrast, preliminary data from our pilot female PTSD+ subjects showed a relatively balanced pattern of increased and decreased expression of genes and an increase in activity of pathways related to immune activation. The results indicate differential patterns of monocyte gene expression in PTSD, and the preliminary data from our female pilot subjects are suggestive of gender dimorphism in biologic pathways activated in PTSD. Changes in immune cell gene expression may contribute to medical morbidity in PTSD